Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer

Since 1941, androgen deprivation therapy has been the primary treatment for metastatic hormone‐sensitive prostate cancer. Androgen deprivation therapy consists of several regimens that vary according to therapeutic modality, as well as treatment schedule. Androgen deprivation therapy initially shows...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of urology 2016-05, Vol.23 (5), p.360-369
Hauptverfasser:	Shiota, Masaki, Eto, Masatoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	abiraterone acetate Androgen Antagonists - therapeutic use androgen deprivation therapy Biomarkers, Tumor Disease Progression enzalutamide hormone-sensitive prostate cancer Humans Male Prostatic Neoplasms, Castration-Resistant - drug therapy taxane Taxoids
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!